2025 Q4 -tulosraportti
Vain PDF
123 päivää sitten
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·5 t sittenWhen talking about CNS data: In a Circio context, «CNS-data» thus means data on how circVec functions in the central nervous system, typically how well the technology can express itself in brain tissue or other relevant CNS cells. It is important because CNS is difficult to treat: delivery to the correct tissue, dose, duration, and safety are major challenges. Therefore, good CNS data can be very valuable for Circio. It is also the case that many still associate Circio's CNS data with 4x. But that number came from circVec 2.1. Today's platform is 4.0. In the eye, one went from 7x with circVec 2.0 to up to 50x with 4.0. This does not mean that the brain will automatically do the same – different tissues cannot be directly compared – but it shows how much the platform has improved since the first CNS data. Now, newer circVec generations will be tested in CNS. This will be one of the most interesting readouts in the second half of the year.
Consider that CNS is the organ with by far the highest natural occurrence of circRNA. - this means that circVec as a protein accelerator, perhaps in the CNS, has an even better effect than we have seen in the other organs so far. Hint hint, Erik Wiklund: "it's going better than expected with the Big Pharma CNS study".
·5 t sittenThe big annual bioconference took place this weekend on another forum. This year's theme was valuation of biotech companies with a special focus on Circio Holding ASA. The conference gathered participants from many other threads and what made the conference special this year was the good participation from several investors who last year argued that they would never invest in Circio, when mcap was at 30- 40 mill and the share price approx 0.60.
·22 t sittenThe message from Circio Holding (signed by Lubor) informs about a planned R&D and general update during a webcast for the first half of the year on 1 September 2026 at 10:00, and encourages shareholders or interested parties to submit any questions in advance.Date and time: 1 September 2026 at 10:00Content: Finances, R&D, business development and ongoing collaborationsAction: Opportunity to submit questions in advance for the webcastCircio now has several collaborations of different nature. If management chooses to spend time on them in the webcast, we can get information about progress, even if they cannot necessarily disclose results or commercial negotiations.
·1 päivä sittenMonday teaser: The market's biggest calculation error in Circio (From v2.1 to v4.0 in CNS) Many believe 4x is the ceiling for Circio in the brain. That is wrong, that number was with the old circVec 2.1! The brain has never been tested with the new, optimized circVec 4.0 until now (Q3 in vivo). Consider this calculation: The eye (which is neural tissue): Went from 7x with the old version to 50x with version 4.0. The brain: Is now to be upgraded from 2.1 to 4.0 for the very first time. Many will likely want to get in here . Good trading week- ·1 päivä sittenWill the market get CAR-T info at the H1 presentation on August 31? It is a topic at the ESGCT presentation in October. In 2025, they presented 40x in heart at ESGCT. But actually, the first info about 40x came at H1 on August 28, 25. If they follow the same procedure this year as well, we might get the first glimpses of CAR-T in not many days.The semi-annual report states August 31st, I thought he meant a follow-up webcast with a deeper update, but they are not updated on the website, so we'll see if they are when it gets closer. It might be true that we'll know something sooner. I have at least sent this in since he said we could submit questions. Sent in Norwegian and English since it will be sent to Erik and Lubor: I am following Circio closely and have some questions I hope you can answer, either in the planned R&D webcast or via email. 1. Board authorization and capital utilization (EGM August 25th) The Board requests renewed authorization to increase the share capital by up to 20 %. What is the primary reason for requesting this authorization now, when the company has already raised approx. 620 MNOK and has runway until 2030? During the warrant period, Erik commented that surplus capital exceeding 300 MNOK could be used to acquire complementary delivery or vector technology. Is the new authorization intended to be used for such strategic opportunities? 2. CNS study (top-5 pharma) Can you provide a status update on the in vivo part of the collaboration? When do you expect the first results? What are the most important success criteria for the study to proceed to licensing discussions? 3. Pipeline, data and further development of circVec Which disease model data (heart, eye or CNS) do you prioritize highest in H2 2026? Have you seen a clear difference between circVec 3.2 and 4.0 in the latest in vivo experiments? You have previously mentioned that further adjustments could lead to a new generation (e.g., circVec 5.0). Are you actively working on the next generation of the platform, and when can we potentially expect data or an update on that? What does the IP situation around circVec look like currently, especially considering the latest patent applications? How important is further strengthening of the patent portfolio for future licensing or acquisition discussions? 4. Strategy going forward With a solid capital position and both Dinah Sah (new) and Robert Burns (from alternate member to ordinary member) on the Board – how do you balance building your own clinical pipeline versus prioritizing more partnerships and potential acquisition of delivery technology? Thanks in advance..
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
Vain PDF
123 päivää sitten
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·5 t sittenWhen talking about CNS data: In a Circio context, «CNS-data» thus means data on how circVec functions in the central nervous system, typically how well the technology can express itself in brain tissue or other relevant CNS cells. It is important because CNS is difficult to treat: delivery to the correct tissue, dose, duration, and safety are major challenges. Therefore, good CNS data can be very valuable for Circio. It is also the case that many still associate Circio's CNS data with 4x. But that number came from circVec 2.1. Today's platform is 4.0. In the eye, one went from 7x with circVec 2.0 to up to 50x with 4.0. This does not mean that the brain will automatically do the same – different tissues cannot be directly compared – but it shows how much the platform has improved since the first CNS data. Now, newer circVec generations will be tested in CNS. This will be one of the most interesting readouts in the second half of the year.Consider that CNS is the organ with by far the highest natural occurrence of circRNA. - this means that circVec as a protein accelerator, perhaps in the CNS, has an even better effect than we have seen in the other organs so far. Hint hint, Erik Wiklund: "it's going better than expected with the Big Pharma CNS study".
- ·5 t sittenThe big annual bioconference took place this weekend on another forum. This year's theme was valuation of biotech companies with a special focus on Circio Holding ASA. The conference gathered participants from many other threads and what made the conference special this year was the good participation from several investors who last year argued that they would never invest in Circio, when mcap was at 30- 40 mill and the share price approx 0.60.
- ·22 t sittenThe message from Circio Holding (signed by Lubor) informs about a planned R&D and general update during a webcast for the first half of the year on 1 September 2026 at 10:00, and encourages shareholders or interested parties to submit any questions in advance.Date and time: 1 September 2026 at 10:00Content: Finances, R&D, business development and ongoing collaborationsAction: Opportunity to submit questions in advance for the webcastCircio now has several collaborations of different nature. If management chooses to spend time on them in the webcast, we can get information about progress, even if they cannot necessarily disclose results or commercial negotiations.
- ·1 päivä sittenMonday teaser: The market's biggest calculation error in Circio (From v2.1 to v4.0 in CNS) Many believe 4x is the ceiling for Circio in the brain. That is wrong, that number was with the old circVec 2.1! The brain has never been tested with the new, optimized circVec 4.0 until now (Q3 in vivo). Consider this calculation: The eye (which is neural tissue): Went from 7x with the old version to 50x with version 4.0. The brain: Is now to be upgraded from 2.1 to 4.0 for the very first time. Many will likely want to get in here . Good trading week
- ·1 päivä sittenWill the market get CAR-T info at the H1 presentation on August 31? It is a topic at the ESGCT presentation in October. In 2025, they presented 40x in heart at ESGCT. But actually, the first info about 40x came at H1 on August 28, 25. If they follow the same procedure this year as well, we might get the first glimpses of CAR-T in not many days.The semi-annual report states August 31st, I thought he meant a follow-up webcast with a deeper update, but they are not updated on the website, so we'll see if they are when it gets closer. It might be true that we'll know something sooner. I have at least sent this in since he said we could submit questions. Sent in Norwegian and English since it will be sent to Erik and Lubor: I am following Circio closely and have some questions I hope you can answer, either in the planned R&D webcast or via email. 1. Board authorization and capital utilization (EGM August 25th) The Board requests renewed authorization to increase the share capital by up to 20 %. What is the primary reason for requesting this authorization now, when the company has already raised approx. 620 MNOK and has runway until 2030? During the warrant period, Erik commented that surplus capital exceeding 300 MNOK could be used to acquire complementary delivery or vector technology. Is the new authorization intended to be used for such strategic opportunities? 2. CNS study (top-5 pharma) Can you provide a status update on the in vivo part of the collaboration? When do you expect the first results? What are the most important success criteria for the study to proceed to licensing discussions? 3. Pipeline, data and further development of circVec Which disease model data (heart, eye or CNS) do you prioritize highest in H2 2026? Have you seen a clear difference between circVec 3.2 and 4.0 in the latest in vivo experiments? You have previously mentioned that further adjustments could lead to a new generation (e.g., circVec 5.0). Are you actively working on the next generation of the platform, and when can we potentially expect data or an update on that? What does the IP situation around circVec look like currently, especially considering the latest patent applications? How important is further strengthening of the patent portfolio for future licensing or acquisition discussions? 4. Strategy going forward With a solid capital position and both Dinah Sah (new) and Robert Burns (from alternate member to ordinary member) on the Board – how do you balance building your own clinical pipeline versus prioritizing more partnerships and potential acquisition of delivery technology? Thanks in advance..
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
2025 Q4 -tulosraportti
Vain PDF
123 päivää sitten
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·5 t sittenWhen talking about CNS data: In a Circio context, «CNS-data» thus means data on how circVec functions in the central nervous system, typically how well the technology can express itself in brain tissue or other relevant CNS cells. It is important because CNS is difficult to treat: delivery to the correct tissue, dose, duration, and safety are major challenges. Therefore, good CNS data can be very valuable for Circio. It is also the case that many still associate Circio's CNS data with 4x. But that number came from circVec 2.1. Today's platform is 4.0. In the eye, one went from 7x with circVec 2.0 to up to 50x with 4.0. This does not mean that the brain will automatically do the same – different tissues cannot be directly compared – but it shows how much the platform has improved since the first CNS data. Now, newer circVec generations will be tested in CNS. This will be one of the most interesting readouts in the second half of the year.Consider that CNS is the organ with by far the highest natural occurrence of circRNA. - this means that circVec as a protein accelerator, perhaps in the CNS, has an even better effect than we have seen in the other organs so far. Hint hint, Erik Wiklund: "it's going better than expected with the Big Pharma CNS study".
- ·5 t sittenThe big annual bioconference took place this weekend on another forum. This year's theme was valuation of biotech companies with a special focus on Circio Holding ASA. The conference gathered participants from many other threads and what made the conference special this year was the good participation from several investors who last year argued that they would never invest in Circio, when mcap was at 30- 40 mill and the share price approx 0.60.
- ·22 t sittenThe message from Circio Holding (signed by Lubor) informs about a planned R&D and general update during a webcast for the first half of the year on 1 September 2026 at 10:00, and encourages shareholders or interested parties to submit any questions in advance.Date and time: 1 September 2026 at 10:00Content: Finances, R&D, business development and ongoing collaborationsAction: Opportunity to submit questions in advance for the webcastCircio now has several collaborations of different nature. If management chooses to spend time on them in the webcast, we can get information about progress, even if they cannot necessarily disclose results or commercial negotiations.
- ·1 päivä sittenMonday teaser: The market's biggest calculation error in Circio (From v2.1 to v4.0 in CNS) Many believe 4x is the ceiling for Circio in the brain. That is wrong, that number was with the old circVec 2.1! The brain has never been tested with the new, optimized circVec 4.0 until now (Q3 in vivo). Consider this calculation: The eye (which is neural tissue): Went from 7x with the old version to 50x with version 4.0. The brain: Is now to be upgraded from 2.1 to 4.0 for the very first time. Many will likely want to get in here . Good trading week
- ·1 päivä sittenWill the market get CAR-T info at the H1 presentation on August 31? It is a topic at the ESGCT presentation in October. In 2025, they presented 40x in heart at ESGCT. But actually, the first info about 40x came at H1 on August 28, 25. If they follow the same procedure this year as well, we might get the first glimpses of CAR-T in not many days.The semi-annual report states August 31st, I thought he meant a follow-up webcast with a deeper update, but they are not updated on the website, so we'll see if they are when it gets closer. It might be true that we'll know something sooner. I have at least sent this in since he said we could submit questions. Sent in Norwegian and English since it will be sent to Erik and Lubor: I am following Circio closely and have some questions I hope you can answer, either in the planned R&D webcast or via email. 1. Board authorization and capital utilization (EGM August 25th) The Board requests renewed authorization to increase the share capital by up to 20 %. What is the primary reason for requesting this authorization now, when the company has already raised approx. 620 MNOK and has runway until 2030? During the warrant period, Erik commented that surplus capital exceeding 300 MNOK could be used to acquire complementary delivery or vector technology. Is the new authorization intended to be used for such strategic opportunities? 2. CNS study (top-5 pharma) Can you provide a status update on the in vivo part of the collaboration? When do you expect the first results? What are the most important success criteria for the study to proceed to licensing discussions? 3. Pipeline, data and further development of circVec Which disease model data (heart, eye or CNS) do you prioritize highest in H2 2026? Have you seen a clear difference between circVec 3.2 and 4.0 in the latest in vivo experiments? You have previously mentioned that further adjustments could lead to a new generation (e.g., circVec 5.0). Are you actively working on the next generation of the platform, and when can we potentially expect data or an update on that? What does the IP situation around circVec look like currently, especially considering the latest patent applications? How important is further strengthening of the patent portfolio for future licensing or acquisition discussions? 4. Strategy going forward With a solid capital position and both Dinah Sah (new) and Robert Burns (from alternate member to ordinary member) on the Board – how do you balance building your own clinical pipeline versus prioritizing more partnerships and potential acquisition of delivery technology? Thanks in advance..
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt